[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.180.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
May 2003

Childhood Vitiligo and TacrolimusImmunomodulating Treatment for an Autoimmune Disease

Arch Dermatol. 2003;139(5):651-654. doi:10.1001/archderm.139.5.651

VITILIGO IS an acquired pigmentary disorder, clinically characterized by the development of white macules caused by damage to melanocytes in the affected skin.1 The prevalence of the disease in the United States and Europe has been estimated at around 1%. Half of all patients develop the disease in childhood and adolescence before age 20 years, making vitiligo an important topic of pediatric dermatology.

First Page Preview View Large
First page PDF preview
First page PDF preview
×